Gemtuzumab ozogamicin in (KMT2A)-rearranged adult acute myeloid leukaemia (AML) in the UK Medical Research Council AML15 and AML16 trials

Richard Dillon, Robert K. Hills, Alan K. Burnett, Nigel H. Russell*

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
JournalBritish Journal of Haematology
DOIs
Publication statusAccepted/In press - 2021

Cite this